Skip to main content

ASCPT 2025 Annual Meeting Main banner

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

M
PII-120
MARFAN: MAXIMIZING ATENOLOL RESPONSE THROUGH FUNCTIONAL ASSESSMENT INVESITGATIONS AMONGST CONNECTIVE TISSUE DISORDERS

Favorite
PII-073
MASS BALANCE, METABOLISM, AND EXCRETION OF [14C] BEXICASERIN IN A SINGLE DOSE RADIOLABEL STUDY IN HEALTHY ADULT MALES.

Favorite
PI-073
MECHANISM-BASED PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF ERYTHROFERRONE: OPTIMIZING RECOMBINANT HUMAN ERYTHROPOIETIN DOSING IN CKD-INDUCED ANEMIA

Favorite
PII-097
MECHANISTIC INSIGHTS INTO CYTOKINE ANTAGONIST-DRUG INTERACTIONS: A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING APPROACH WITH TOCILIZUMAB AS A CASE STUDY

Favorite
PI-097
MECHANISTIC MODELING OF SPATIAL HETEROGENEITY OF DRUG PENETRATION AND EXPOSURE IN THE HUMAN CENTRAL NERVOUS SYSTEM AND BRAIN TUMORS

Favorite
E-001
MEDICATIONS AND ACUTE HEMOLYSIS IN G6PD-DEFICIENT PATIENTS A REAL-WORLD STUDY. Received February 25, 2024; accepted May 20, 2024. doi:10.1002/cpt.3333

Favorite
PII-127
MEETING CLINICAL TRIAL RECRUITMENT MILESTONES IN ACADEMIC CENTERS: A DATA-DRIVEN VISUAL APPROACH

Favorite
PII-051
METHYLATION PROFILING AND PATHWAY ENRICHMENT ANALYSIS REVEAL EPIGENETIC MECHANISMS IN CARFILZOMIB-RELATED CARDIOTOXICITY IN MULTIPLE MYELOMA PATIENTS .

Favorite
PII-008
MICRORNA REGULATING SEL1L INVOLVED IN THE PATHOGENESIS OF PARKINSON'S DISEASE AND ITS EXPRESSION LEVELS IN PATIENT PLASMA.

Favorite
PWII-004
MITIGATING CARDIOTOXICITY OF TRASTUZUMAB AND DOXORUBICIN COMBINATION THERAPY WITH AN INTEGRATED TRANSLATIONAL AND QUANTITATIVE SYSTEMS TOXICOLOGY AND PBPK/PD MODELING APPROACH

Favorite
PT-028
MITIGATING CARDIOTOXICITY OF TRASTUZUMAB AND DOXORUBICIN COMBINATION THERAPY WITH AN INTEGRATED TRANSLATIONAL AND QUANTITATIVE SYSTEMS TOXICOLOGY AND PBPK/PD MODELING APPROACH

Favorite
PII-074
MODEL INFORMED DOSE OPTIMIZATION OF BALSTILIMAB TO SUPPORT FIXED DOSING ALONE AND IN COMBINATION WITH BOTENSILIMAB IN PATIENTS WITH SOLID TUMORS.

Favorite
PI-032
MODEL INFORMED DOSE OPTIMIZATION OF BOTENSILIMAB ALONE AND IN COMBINATION WITH BALSTILIMAB IN PATIENTS WITH SOLID TUMORS

Favorite
PI-074
MODEL-BASED DRUG DEVELOPMENT CONSIDERATIONS: ZANIDATAMAB IN PATIENTS WITH HER2 EXPRESSING BILIARY TRACT CANCER (BTC)

Favorite
PII-075
MODEL-BASED EVALUATION OF DELANDISTROGENE MOXEPARVOVEC ADENO-ASSOCIATED VIRUS PHARMACOKINETICS AND SAFETY IMPLICATIONS

Favorite
PI-075
MODEL-BASED META-ANALYSIS OF PLACEBO-RESPONSE FOR MONTHLY MIGRAINE DAYS IN MIGRAINE PREVENTION CLINICAL TRIALS FROM LITERATURE

Favorite
PII-076
MODEL-ESTIMATED TISSUE PHARMACOLOGY AS A SURROGATE OF MONOCLONAL ANTIBODY CLINICAL EFFICACY DOSE RESPONSE: CASE STUDY USING DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS.

Favorite
PII-015
MODELING AND SIMULATION ANALYSIS TO SUPPORT DOSE SELECTION FOR MAM01, A NOVEL ANTI-CIRCUMSPOROZOITE PROTEIN MONOCLONAL ANTIBODY, IN UPCOMING TRIALS

Favorite
LB-001
MODELING AND SIMULATION OF POLYAMINE KINETICS DURING ACUTE KIDNEY INJURY

Favorite
PII-032
MOVING TOWARD "FIT-FOR-PURPOSE" QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODELING IN DRUG DEVELOPMENT: CASE EXAMPLES IN ONCOLOGY.

Favorite
PI-033
MULTISTATE MODEL TO INVESTIGATE OVERALL SURVIVAL (OS) FROM COPANLISIB PIVOTAL TRIALS.

Favorite